Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm
A legfontosabb adatok
- Hol
- Rochester (Egyesült Államok)A helyszín megnézése
- Fázis
- 3. fázis
Helyszínek itt: Egyesült Államok
- Mayo ClinicRochester, Egyesült ÁllamokContact: Pietro Di Santo, MD PhDToborzás még nem indult
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- Ottawa Heart Institute Research Corporation
- Azonosító
- NCT06281977
- A regiszteradat frissítve
- 2026. július 7.
- Eredeti leírás
The objective of this study is to determine if there is a meaningful benefit to using the sedative medication dexmedetomidine in the acute treatment of patients with recurrent ventricular arrhythmias, known as electrical storm. This will be a multi-centre, double-blinded, placebo-controlled, randomized trial. Patients with electrical storm will be randomized to receive 48 to 72 hours of dexmedetomidine or placebo as part of their initial treatment in an intensive care unit.A teljes eredeti leírásKevesebb
The objective of this study is to determine if there is a meaningful benefit to using the sedative medication dexmedetomidine in the acute treatment of patients with recurrent ventricular arrhythmias, known as electrical storm. This will be a multi-centre, double-blinded, placebo-controlled, randomized trial. Patients with electrical storm will be randomized to receive 48 to 72 hours of dexmedetomidine or placebo as part of their initial treatment in an intensive care unit.
Bevonási feltételek: All patients admitted to an intensive care unit with electrical storm over the age of 18 years will be approached for enrollment.
Kizáró feltételek: Cardiac arrest(s) with a no-flow and low-flow total time of greater than 10 minutes prior to recruitment; Patients who have received dexmedetomidine or clonidine during the 24 hours prior to randomization; Refractory shock lasting for more than 30 minutes unrelated to ventricular arrhythmias (VAs), defined as requiring two or more vasopressors; ST-segment elevation myocardial infarction (STEMI)-induced VA with signs of active ischemia; Bradycardia with heart rate less than 40 beats per minute, bradycardia-induced ventricular tachyarrhythmia, second degree Mobitz type 2 or greater atrioventricular block in the absence of a pacemaker; Known dexmedetomidine allergy or intolerance; SCAI class D or E cardiogenic shock; Pregnancy; Inability to obtain consent from patient or substitute decision maker.